SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Fransson Göran)
 

Sökning: WFRF:(Fransson Göran) > Cost-effectiveness ...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003727naa a2200373 4500
001oai:DiVA.org:liu-45524
003SwePub
008091011s2005 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:1929637
024a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-455242 URI
024a https://doi.org/10.1016/j.ahj.2004.07.0202 DOI
024a http://kipublications.ki.se/Default.aspx?queryparsed=id:19296372 URI
040 a (SwePub)liud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a for2 swepub-publicationtype
100a Aspelin, P.u Karolinska Institutet4 aut
2451 0a Cost-effectiveness of iodixanol in patients at high risk of contrast-induced nephropathy
264 1b Elsevier BV,c 2005
338 a print2 rdacarrier
520 a Background: Acute renal failure after contrast-induced nephropathy is a clinically important and costly complication after the use of iodine-based contrast media. We investigated the cost and cost-effectiveness of 2 contrast media in patients at high risk of contrast-induced nephropathy. Methods: The analyses were based on a randomized, prospective, multinational clinical study comparing the nephrotoxic effects of an isosmolar nonionic contrast medium, iodixanol, with those of a low-osmolar nonionic contrast medium, iohexol. Resource utilization data were obtained from the study and from a retrospective review of patients' hospital records. Swedish, German, and French unit prices were applied to resources used. Between-group differences in average costs were analyzed using a nonparametric bootstrap method. Results: Resource utilization data for 125 patients were analyzed. Seven contrast media-related serious adverse reactions, of which 6 were acute renal failures, were noted in 6 patients receiving iohexol. Two patients in the iodixanol group had 1 nonserious reaction each. The mean hospitalization cost per patient was €489, €573, and €393 lower after iodixanol than after iohexol using Swedish, German, and French unit prices, respectively. The mean per-patient costs of treating adverse drug reactions were €371, €399, and €445 lower after iodixanol than after iohexol, using the respective unit prices (P = 0.01). Iodixanol was cost-effective compared with iohexol, with both lower costs and better effects related to fewer adverse drug reactions. Conclusions: The isosmolar contrast medium iodixanol appears to be cost-effective when compared with a low-osmolar contrast medium, iohexol, in diabetic patients with renal impairment undergoing angiography. © 2005, Elsevier Inc. All rights reserved.
653 a MEDICINE
653 a MEDICIN
700a Aubry, P.u Department of Cardiology, Ctr. Hosp. Universitaire Bichat, Paris, France4 aut
700a Fransson, Sven Göranu Östergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Institutionen för medicin och vård,Kardiologiska kliniken4 aut0 (Swepub:liu)svefr70
700a Strasser, R.u Department of Cardiology, Heart Center, University of Technology, Dresden, Germany4 aut
700a Willenbrock, R.u Department of Cardiology, Hospital St. Elisabeth, Halle, Germany4 aut
700a Lundkvist, J.u Karolinska Institutet4 aut
710a Karolinska Institutetb Department of Cardiology, Ctr. Hosp. Universitaire Bichat, Paris, France4 org
773t American Heart Journald : Elsevier BVg 149:2, s. 298-303q 149:2<298-303x 0002-8703x 1097-6744
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-45524
8564 8u https://doi.org/10.1016/j.ahj.2004.07.020
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:1929637

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy